CANNASOUTH LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.098 NZD | +2.08% |
|
-.--% | -26.32% |
| Apr. 15 | Cannasouth Terminates COO | MT |
| Apr. 11 | New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns | MT |
More news
| 1 day | +2.08% | ||
| 1 month | +2.08% | ||
| 3 months | -5.77% | ||
| 6 months | -47.03% | ||
| Current year | -26.32% |
1 month
0.10
0.10
Current year
0.100.15
1 year
0.100.32
3 years
0.100.32
5 years
0.100.32
10 years
0.100.32
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Booysen
CMP | Compliance Officer | - | - |
David Gill
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-31 |
Tony Clark
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peng Ho
CHM | Chairman | 65 | 18-09-25 |
Christine Pears
BRD | Director/Board Member | - | 21-06-28 |
Mark Scapens
BRD | Director/Board Member | - | - |
Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.32% | 19.12M | |
| -0.02% | 42.11B | |
| +46.00% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- CBD Stock
